Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25288596 | 0.76 | — | — | |
| SCHEMBL6932628 | 0.76 | — | — | |
| SCHEMBL131883 | 0.75 | — | — | |
| SCHEMBL24043682 | 0.74 | — | — | |
| SCHEMBL11348362 | 0.74 | — | — | |
| SCHEMBL9160620 | 0.71 | — | — | |
| SCHEMBL127436 | 0.71 | — | — | |
| SCHEMBL7120974 | 0.71 | — | — | |
| SCHEMBL4606699 | 0.70 | MGAM (0.50) | — | |
| SCHEMBL11274998 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1136474-B1 | 1-Acetyl-5-bromo-4,6-dimethylindoline | SANKYO CO (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-0782986-B1 | NOVEL HETEROCYCLIC DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | SANKYO CO (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-6489475-B2 | ENZYME INHIBITOR; LIPOPEROXIDATION INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 2002-12-03 | — | — | US | disclosed |
| US-6414012-B1 | CARDIOVASCULAR DISORDERS; ANTICHOLESTEROL AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-07-02 | — | — | US | disclosed |
| EP-1136474-A1 | 1-Acetyl-5-bromo-4,6-dimethyl-indoline | SANKYO COMPANY LIMITED (JP) | 2001-09-26 | — | — | EP | disclosed |
| US-20010014740-A1 | Enzyme inhibitor; lipoperoxidation inhibitor | MATSUI HIROSHI (JP) | 2001-08-16 | — | — | US | disclosed |
| US-6127403-A | AN ENZYME INHIBITOR FOR TREATING ARTERIOSCLEROTIC LESIONS OF ARTERIOSCLEROSIS, HYPERLIPEMIA AND DIABETES, AS WELL AS ISCHEMIC DISEASES OF BRAIN, HEART | SANKYO COMPANY, LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| US-5990150-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS AND LIPOPEROXIDATION INHIBITORY ACTIVITY; ANTILIPEMIA; ARTERIOSCLEROSIS; ANTICHOLESTEROL AGENTS; ANTIISCHEMIC AGENTS; SIDE EFFECT REDUCTION | SANKYO COMPANY, LTD. (JP) | 1999-11-23 | — | — | US | disclosed |
| EP-0782986-A1 | NOVEL HETEROCYCLIC DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1997-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014740-A1 | Enzyme inhibitor; lipoperoxidation inhibitor | ACAT2, ACOX1, ACAT1 | CA12 2685/4885CA1 737/4885CA2 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.